Retroperitoneal sarcomas: Patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: A multicenter analysis of the French Sarcoma Group

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 730-734

  Toulmonde, M ^a   Bonvalot, S ^b   Ray Coquard, I ^c   Stoeckle, E ^a   Riou, O ^d   Isambert, N ^e   Bompas, E ^f   Penel, N ^g   Delcambre Lair, C ^h   Saada, E ⁱ   Lecesne, A ^b   Le pechoux C ^b   Blay, J Y ^c   Piperno Neumann, S ^j   Chevreau, C ^k   Bay, J O ^l   Brouste, V ^a   Terrier, P ^b   Ranchere Vince D ^c   Neuville, A ^a   Italiano, A ^a   more..

^a INSTITUT BERGONIÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE VAL D AURELLE   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j INSTITUT CURIE   (France)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l CENTRE JEAN PERRIN   (France)

more..

Author keywords

Chemotherapy; Palliative; Prognosis; Retroperitoneal sarcoma

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RETROPERITONEAL SARCOMA; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT RESPONSE;

CHEMOTHERAPY; PALLIATIVE; PROGNOSIS; RETROPERITONEAL SARCOMA;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELIVERY OF HEALTH CARE; DISEASE PROGRESSION; FEMALE; FRANCE; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84896810952     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt576     Document Type: Article

References (29)

1. Raut CP, Pisters PW. Retroperitoneal sarcomas: combined-modality treatment approaches. J Surg Oncol 2006; 94: 81-87.
2. Huang HY, Brennan MF, Singer S et al. Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation. Mod Pathol 2005; 18: 976-984.
3. Henricks WH, Chu YC, Goldblum JR et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21: 271-281.
4. Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcoma. J Surg Oncol 2008; 98: 607-610.
5. van Dalen T, Hoekstra HJ, van Geel AN et al. Locoregional recurrence of retroperitoneal soft tissue sarcoma: second chance of cure for selected patients. Eur J Surg Oncol 2001; 27: 564-568.
6. Grobmyer SR, Wilson JP, Apel B et al. Recurrent retroperitoneal sarcoma: impact of biology and therapy on outcomes. J Am Coll Surg 2010; 210: 602-608, 608-610.
7. Lewis JJ, Leung D, WoodruffJM et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228: 355-365.
8. Anaya DA, Lahat G, Liu J et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg 2009; 249: 137-142.
9. Rossi CR, Casali P, Kusamura S et al. The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol 2008; 98: 291-294.
10. Shibata D, Lewis JJ, Leung DH et al. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg 2001; 193: 373-379.
11. Jaques DP, Coit DG, Hajdu SI et al. Management of primary and recurrent softtissue sarcoma of the retroperitoneum. Ann Surg 1990; 212: 51-59.
12. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
13. Italiano A, Toulmonde M, Bui-Nguyen B. Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines. Bull Cancer 2010; 97: 679-686.
14. Penel N, van Glabbeke M, Marreaud S et al. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011; 22: 1266-1272.
15. Italiano A, Toulmonde M, CioffiA et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012; 23: 1601-1607.
16. Jones RL, Fisher C, Al-Muderis O et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41: 2853-2860.
17. Munene G, Mack LA, Temple WJ. Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy. Ann Surg Oncol 2011; 18: 207-213.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991; 9: 191-192.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
22. Cox DR. Regression modelas and life-tables. J Stat Soc (Ser B) 1972; 34: 187-202.
23. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10: 833-841.
24. Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v198-v203.
25. van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
26. Karavasilis V, Seddon BM, Ashley S et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112: 1585-1591.
27. Yeh JJ, Singer S, Brennan MF et al. Effectiveness of palliative procedures for intraabdominal sarcomas. Ann Surg Oncol 2005; 12: 1084-1089.
28. Lochan R, French JJ, Manas DM. Surgery for retroperitoneal soft tissue sarcomas: aggressive re-resection of recurrent disease is possible. Ann R Coll Surg Engl 2011; 93: 39-43.
29. Ray-Coquard I, Blay JY, Italiano A et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13: 1133-1140.